ArticleTherapeutic advances in medical oncology2023

Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer.

Jiangping Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.